[18F]FMeNER-D2: Reliable fully-automated synthesis for visualization of the norepinephrine transporter  by Rami-Mark, Christina et al.
Nuclear Medicine and Biology 40 (2013) 1049–1054
Contents lists available at ScienceDirect
Nuclear Medicine and Biology
j ourna l homepage: www.e lsev ie r .com/ locate /nucmedbio[18F]FMeNER-D2: Reliable fully-automated synthesis for visualization of the
norepinephrine transporter
Christina Rami-Mark a,b, Ming-Rong Zhang c, Markus Mitterhauser a,d,
Rupert Lanzenberger e, Marcus Hacker a, Wolfgang Wadsak a,b,⁎
a Radiochemistry and Biomarker Development Unit, Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Austria
b Department of Inorganic Chemistry, University of Vienna, Austria
c Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan
d Hospital Pharmacy of the General Hospital of Vienna, Austria
e Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria
a b s t r a c ta r t i c l e i n f o⁎ Corresponding author. Medical University of Vien
Medicine, Radiochemistry and Biomarker Development
20, A-1090 Vienna, Austria. Tel.: +43 1 40400 5255; fax
E-mail address: wolfgang.wadsak@meduniwien.ac.at
0969-8051/$ – see front matter © 2013 Elsevier Inc. Th
http://dx.doi.org/10.1016/j.nucmedbio.2013.08.007Article history:
Received 25 June 2013
Received in revised form 16 August 2013









Purpose: In neurodegenerative diseases and neuropsychiatric disorders dysregulation of the norepinephrine
transporter (NET) has been reported. For visualization of NET availability and occupancy in the human brain
PET imaging can be used. Therefore, selective NET-PET tracers with high afﬁnity are required. Amongst these,
[18F]FMeNER-D2 is showing the best results so far. Furthermore, a reliable fully automated radiosynthesis is a
prerequisite for successful application of PET-tracers.
The aim of this work was the automation of [18F]FMeNER-D2 radiolabelling for subsequent clinical use. The
presented study comprises 25 automated large-scale syntheses, which were directly applied to healthy
volunteers and adult patients suffering from attention deﬁcit hyperactivity disorder (ADHD). Procedures:
Synthesis of [18F]FMeNER-D2 was automated within a Nuclear Interface Module. Starting from 20–30 GBq
[18F]ﬂuoride, azeotropic drying, reaction with Br2CD2, distillation of 1-bromo-2-[
18F]ﬂuoromethane-D2 ([18F]
BFM) and reaction of the pure [18F]BFM with unprotected precursor NER were optimized and completely
automated. HPLC puriﬁcation and SPE procedure were completed, formulation and sterile ﬁltration were
achieved on-line and full quality control was performed.
Results: Puriﬁed product was obtained in a fully automated synthesis in clinical scale allowing maximum
radiation safety and routine production under GMP-like manner. So far, more than 25 fully automated
syntheses were successfully performed, yielding 1.0–2.5 GBq of formulated [18F]FMeNER-D2 with speciﬁc
activities between 430 and 1707 GBq/μmol within 95 min total preparation time.
Conclusions: A ﬁrst fully automated [18F]FMeNER-D2 synthesis was established, allowing routine production
of this NET-PET tracer under maximum radiation safety and standardization.
© 2013 Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/3.0/).1. Introduction
The norepinephrine transporter (NET) is one of themajor targets in
neuropsychiatric and neurodegenerative diseases like attention deﬁcit
hyperactivity disorder (ADHD), depression, Alzheimer’s disease (AD),
Parkinson’s disease (PD) and substance abuse [1]. For treatment of
these diseases, selective norepinephrine (NE) reuptake inhibitors
(SNRI) are commonly used, which are typically based on reboxetine.
The NET itself facilitates the synaptic reuptake of NE from the synaptic
cleft at the presynaptic terminals. Blocking of this transporter prolongs
the NE action in the synapse, due to an increase in the concentration of
NE in the cleft. Perturbation of the noradrenergic system (and theNET-na - Department of Nuclear
Unit, Waehringer Guertel 18-
: +43 1 40400 1559.
(W. Wadsak).
is is an open access article under texpression) has been reported to trigger many neuropsychiatric
disorders and neurodegenerative diseases. Especially, in the locus
coeruleus (LC) a reduction of NET levels has been shown in major
depression, AD and PD [1–3]. Furthermore, also in ADHD a dysregula-
tion of the NE system was reported [2].
For gaining insight in NET availability and dynamics in both
healthy and diseased human brains, a non-invasive molecular
imaging protocol has been developed using positron emission
tomography (PET). Thus, speciﬁc and selective NET-PET radioligands
are needed. One of the major prerequisites on these candidate tracers
is their afﬁnity towards NET, especially when considering the very low
density of NET in cerebellum, striatum and human insular cortex
[3–8]. Visualization of NET-rich regions like LC, where NET density
is 4–8-fold higher, can be also achieved using ligands with slightly
lower afﬁnity [4,7,9]. Besides, afﬁnity of the candidate ligands
correlates with their binding kinetics, i.e. longer equilibration times
for high-afﬁnity substances (e.g. [125I]iodo-nisoxetine (Ki = 0.7 nM)he CC BY license (http://creativecommons.org/licenses/by/3.0/).
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selectivity of the tracers towards NET is required for feasible NET-PET
imaging, since NET displays a high similarity to dopamine transporter
(DAT) and serotonin transporter (SERT), but shows a signiﬁcantly
lower density in the human brain [5,12,13].
Most described NET-PET tracers used in clinical studies are
derived from reboxetine as known NET-selective compound.
Both 11C-methylated and 18F-ﬂuoroethylated tracers were proposed
[9,14–20]. Thereof, [18F]FMeNER-D2 ((S,S)-2-(α-(2-[18F]ﬂuoro[2H2]
methoxyphenoxy) benzyl)morpholine) is so far displaying best
properties regarding afﬁnity, selectivity and stability. [18F]FMeNER-
D2 was developed at the Karolinska Institute (Sweden) in 2004 by
Schou and co-workers (Fig. 1) [21–23].
Major drawbacks of this NET-PET tracer were the complexity of
the radiosynthesis and lack of an automated preparation sequence.
Thus the aim of this work was the set-up of a reliable automated
production of [18F]FMeNER-D2 allowing for human NET-PET studies.
With this computer-controlled fully-automated synthesis, more than
25 patients were injected with the so-produced [18F]FMeNER-D2 at
a dose of 4.7 MBq/kg body weight and, so far, subsequent NET PET
scans were successfully acquired.
2. Materials and methods
2.1. Materials
Precursor (S,S)-NER (=(S,S)-norethyl-reboxetine, =(2S, 3S)-2-[α-
(2-hydroxyphenoxy) benzyl]morpholine) and reference standard (S,S)-
FMeNER-D2*TFA ((S,S)-2-[α-(2-(dideutero ﬂuoromethoxy)phenoxy)
benzyl]morpholine triﬂuoroacetate) were obtained from PharmaSynth
AS (Tartu, Estonia).
Acetonitrile (ACN for synthesis of DNA, ≥99.9% (GC) and ACN
HPLC grade), dimethylformamide (DMF, p.a, dried over molecular
sieves (4 Å)), dibromomethane-d2 (99 atom% D, copper stabilized),
sodium hydroxide, methanol (MeOH, CHROMASOLV®, for HPLC,
≥99.9%), ammonium formate, Kryptoﬁx K2.2.2 (4,7,13,16,21,24-
hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane) and ethanol (absolute)
were purchased from Sigma-Aldrich (Vienna, Austria). Anion-
exchange cartridges (PS-HCO3) for [18F]ﬂuoride ﬁxation were
purchased from Macherey-Nagel (Dueren, Germany). Sterile water
was purchased from Meditrade Medicare Medizinprodukte (Kufstein,
Austria). Phosphate buffer (125 mM) was prepared by dissolving
0.224 g sodium dihydrogen phosphate-monohydrate and 1.935 g
disodium hydrogen phosphate-dihydrate (both from Merck, Darm-
stadt, Germany) in 100 mL sterile water. For solid phase extraction
C18 plus SepPak® cartridges and Silica plus long SepPak® cartridges
were purchased from Waters (Waters® Associates Milford, USA). For
formulation of the product 0.9% saline solution from B. Braun
(Melsungen, Germany), 3% saline solution (Landesapotheke Salzburg,
Austria) and 125 mM Phosphate buffer) were used. Low-protein
binding Millex® GS 0.22 μm sterile ﬁlters were obtained fromFig. 1. Structures of NERMillipore (Bedford, USA). All other chemicals and solvents for the
syntheses and radiosyntheses were obtained fromMerck (Darmstadt,
Germany) and Sigma-Aldrich with at least analytical grade and used
without further puriﬁcation.
2.2. Instrumentation
[18F]Fluoride was producedwithin a GE PET trace cyclotron via 18O
(p,n)18F reaction (16.5-MeV protons; GE Medical Systems, Uppsala,
Sweden). H218O (HYOX18; N 98%) was obtained from Rotem Europe
(Leipzig, Germany).
Evaluation of reaction conditions was performed manually in a
lead-shielded hood with small quantities of initial radioactivity
(b1 GBq). After optimization, [18F]FMeNER-D2 synthesis was auto-
mated within a Nuclear Interface synthesizer (GE Healthcare,
Sweden), remotely controlled by a standard laptop with dedicated
processing software (Fig. 3).
Puriﬁcation of [18F]FMeNER was performed by semi-preparative
reversed phase HPLC using the built-in semi-preparative HPLC system
equipped with a radioactivity-, a UV-detector (Linear Instruments Model
200 Detector UV/VIS) and a LaPrep HPLC pump (VWR International,
Radnor, USA). A Phenomenex® Gemini, C-18 column with TMS end-
capping, 10 μm,250 × 10mm(Phenomenex®,Aschaffenburg,Germany)
and a mobile phase of MeOH/0.1 M ammonium formate (AMF) in water
50/50 v/v% at a ﬂow rate of 12 mL/min was used for puriﬁcation.
Analytical HPLC was performed on Merck-Hitachi LaChrom HPLC
system (L-7100 pump; LaChrom L-7400 UV detector at 254 nm) and a
NaI radio-detector (Bertholdt Technologies, Bad Wildbach, Germany)
using Raytest software (Raytest, Straubenhardt, Germany). A Phe-
nomenex Prodigy Phenyl-PH3 column; 250 × 4.6 mm, 5 μm (Phe-
nomenex®, Aschaffenburg, Germany) and a mobile phase consisting
of ACN/0.1 M AMF in water 50/50 %v/v at a ﬂow rate of 2 mL/min was
used. The osmolality was measured with a Wescor osmometer
Vapro® 5600 (Sanova Medical Systems, Vienna, Austria) and pH
was measured using a WTW inoLab 740 pH meter (WTW, Weilheim,
Germany). GC-Analysis was performed with a Bruker Gas Chroma-
tography System 430-GC. Radio-TLC Analysis was performed using
silica gel 60 RP-18 F254S plates from Merck (Darmstadt, Germany)
with a mobile phase consisting of ACN/water 70%/30% v/v. Analyses of
radio-TLC plates were done using a Canberra-Packard Instant Imager
(Perkin Elmer, Watford, UK).
PET scans were performed in the Department of Nuclear Medicine,
Medical University Vienna, using a GE Advance PET-scanner and kinetic
model was done with PMOD 3.0 using a two compartment model.
3. Methods
3.1. Preparation of 1-bromo-2-[18F]ﬂuoromethane-d2 ([18F]BFM)
In Fig. 2 the reaction scheme for the synthesis of [18F]BFM and [18F]
FMeNER-D2 is outlined.and FMeNER-D2.
Fig. 2. Reaction scheme for [18F]FMeNER-D2.
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reaction and trapped on an anion exchange cartridge (PS-HCO3). It
was eluted from the cartridge using 0.8 mL of solution containing
(20 mg/mL, 53.2 μmol/mL) Kryptoﬁx 2.2.2 and (4.5 mg/mL,
33.2 μmol/mL) K2CO3 in ACN/water 80%/20% v/v. To test the inﬂuence
of the quality of the water used on the speciﬁc activity ‘trace select
water’ was compared with compared with ‘aqua ad injectabilia’.
After complete evaporation, azeotropic drying was performed
iteratively by twofold addition of 0.8 mL ACN. For optimization of
[18F]BFM synthesis, the dried ﬂuoride was split and cooled to 20 °C
and 50 μL dibromomethane-d2 in 500 μL ACN, DMF or o-dichloro-
benzene was added. The vessel was sealed tightly and the mixture
heated (90 °C, 100 °C) for 5 min. The crude solution containing [18F]
ﬂuoride, dibromomethane-d2 and [18F]BFM was cooled to RT and
distilled under different conditions for optimization purpose: a
smooth He stream (10 ml/min, 30 mL/min and 40 mL/min) was
applied over (a) an empty, sealed 2 mL glass vial; (b) 2 Omniﬁt
cartridges ﬁlled with silica in sequence; and (c) 4 silica plus SepPak®
cartridges linked in series. The volatile [18F]BFM was trapped in a
second vessel containing 400 μL DMF (at RT or cooled at −20 °C in
advance). The chemical and radiochemical purity of the product was
assessed by analytical HPLC. The [18F]BFM solution was directly used
for the next step of synthesis.
3.2. Synthesis of [18F]FMeNER-D2
Synthesis was performed according to Schou et al [22]. Precursor
NER (1 mg; 3.5 nmol) was dissolved in 200 μL DMF and 6 μL of
aqueous 5 M NaOH was added. After addition of 400 μL of the freshly
produced [18F]BFM in DMF, the reaction vessel was sealed and the
mixture heated to 90 °C for 5 min. The crude reaction mixture was
analyzed by analytical HPLC and TLC.
3.3. Automation of radiosynthesis
Automation of synthesis was done within a Nuclear Interface
module using the optimized conditions.
[18F]Fluoride (20–30 GBq) was transferred into a lead shielded hot
cell and connected to the V55 target water line (Fig. 3). [18F]F− was
sucked over the anion exchange cartridge using a vacuum pump (V55
→a, V56→a, V19, V20, V21→b, vacuum pump) and the 18O enriched
water recovered. [18F]Fluoride was eluted from the PS-HCO3 cartridge
into the reactor 1 by priming (via V55→b, V56→b, V8, V18, V20→b,
V21 and vacuum pump) of 0.8 mL elution solution containing K 2.2.2
and potassium carbonate in ACN/trace select water 80/20). Then, [18F]
ﬂuoride was azeotropically dried by heating to 100 °C for 5 min.
Drying was completed by elevation of temperature to 120 °C for
2 min. Then, the vessel was cooled to 40 °C and 0.8 mL ACN was
added over the same lines as the elution solution. After drying,
another portion of ACN was added from vial 1 (using Helium from
V22) and evaporated to complete dryness. The thoroughly driedﬂuoride was cooled to 20 °C and dibromomethane-d2 (50 μL) in
500 μL ACNwas added via vial 2. The vessel was sealed tightly and the
mixture heated to 100 °C for 5 min. After cooling reactor 1 to 28 °C,
the second reactor containing 400 μL DMF was cooled to −20 °C.
Puriﬁcation by distillation was performed over 4 silica plus SepPak®
cartridges using a smooth He stream (1 min with 10 mL/min; then
40 mL/min for 10–15 min) and the pure [18F]BFM trapped in reactor 2
(by bubbling inside the DMF through a peek tubing (V52)). After a
plateau of activity in the second reactor was reached, distillation was
stopped and precursor NER (1 mg in 200 μL DMF + 6 μL 5 M NaOH)
was transferred into reactor 2 via vial 3. The reaction mixture was
sealed and alkylation was performed for 5 min at 90 °C. The reaction
was cooled to RT and quenched by addition of 1 mLwater (vial 7). The
crude product solution was transferred to the prep HPLC injection
loop and automatically injected onto the column (Phenomenex
Gemini, MeOH/0.1 M AMF 50%/50% v/v; 12 mL ﬂow rate) using a
ﬂuid detector. The product fraction was cut into a 100 mL bulb and
diluted with 80 mL water. After removal of solvents by reversed-
phase SPE (C-18 plus SepPak) [24], the product was washed with
10 mL water (vial 6) and eluted with 1.5 mL EtOH (vial 5) into the
product collection vessel containing 4 mL 0.9% saline, 1 mL 125 mM
phosphate buffer (pH 7.4) and 1 mL 3% saline. The tubings were
washed with another 5 mL saline (vial 4) and the formulated product
was passed over a 0.22 μm sterile ﬁlter into an evacuated sterile vial
containing a further 5 mL 0.9% saline. Final volume was 17.5 mL,
containing 8.5% ethanol. Puriﬁed [18F]FMeNER-D2 was analyzed by
analytical HPLC, GC and TLC; pH and osmolality were measured and a
y-spectrum was recorded. Testing for endotoxins and sterility was
performed retrospectively. Total quality control was performed
according to the guidelines presented in the European Pharmacopoeia
and using routine procedures at the PET Centre of the Vienna General
Hospital, Medical University of Vienna. Speciﬁc radioactivity was
assessed by quantiﬁcation of the non-radioactive product (HPLC UV
channel at 254 nm) and determination of overall radiochemical yield
(GBq at end of synthesis).4. Results
4.1. Preparation of 1-bromo-2-[18F]ﬂuoromethane-d2 ([18F]BFM)
Small scale reactions evinced that reaction of [18F]ﬂuoride with
dibromomethane-d2 was highly dependent on the solvent used.
Using DMF as solvent did only result in 5%–25% [18F]BFM, even at
elevated temperatures (90–150 °C) only 75%–95% of [18F]ﬂuoride
was recovered. Nucleophilic substitution in o-DCB at 100 °C, com-
monly used for synthesis of 1-bromo2-[18F]ﬂuoroethane [25–28],
evinced 52% ± 5% radiochemical incorporation. Interestingly, a
second radioactive byproduct was formed, eluting from the HPLC at
almost the same retention time as the later formed [18F]FMeNER-D2.
Synthesis of [18F]BFM in ACN for 5 min at 100 °C showed the best
Fig. 3. Set-up of the automated process of [18F]FMeNER-D2 synthesis.
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by-product formation.
Puriﬁcation of the crude [18F]BFM is mandatory, and was per-
formed by distillation. For the removal of ACN and dibromomethane-
d2 three different approaches were tested. At ﬁrst, an empty 2 mL
glass vial was linked in between the crude (reactor 1) and the DMF
trap (reactor 2). Unfortunately, almost all of the product was retained
within this trap, and only very small amounts of [18F]BFM could be
obtained in the DMF distillate. Also elevation of temperature from RT
to 50 °C did not result in much higher activity in the distillate; on the
contrary, larger quantities of ACN were spilled into the product trap.
Since it was crucial to remove ACN for the next reaction step, this
set-up was discarded. Next, two Omniﬁt cartridges (3 mm/25 mm
each) were ﬁlled with silica (80–100mesh, each 300 mg) and secured
with glass wool and frits. These were linked in series and inserted
between the crude product vial and the DMF trap. Hereby, all ACN and
dibromomethane were trapped on the columns, but also almost the
entire product was retained on the column. The quantities of product
within the DMF trap were too small for further reactions. Therefore, a
third approach of puriﬁcation was tried: linking 4 silica plus SepPak®
cartridges in series. Using this setup, the removal of ACN and
dibromomethane-d2 could be achieved at RT, and also the amounts
of trapped [18F]BFM (N97% radiochemical purity) were sufﬁcient for
further syntheses. After 10–15 min, no further product was distilled
using 40 mL/min He.4.2. Synthesis of FMeNER-D2
The distilled [18F]BFM (in 400 μL DMF) was reacted with 1 mg
NER in 200 μL DMF and 6 μL 5 M NaOH yielding 95%–99% radio-
chemical incorporation after 5 min at 90 °C. For puriﬁcation, a
preparative HPLC assay was developed and allowed the separation
of all compounds. The retention times were 1.62 min (k’ = 0) for
[18F]ﬂuoride, 2.50 min (k’ = 0.55) for precursor NER, 2.97 min
(k’ = 0.84) for [18F]BFM, 6.77 min (k’ = 3.19) for Br2CD2 and
8.83 min (k’ = 4.46) for [18F]FMeNER-D2. Less than 5% of radioactiveimpuritieswere detected in all [18F]FMeNER-D2 syntheses, so far. After
dilution of the product fraction (8–9.5 min) with 80 mL water, SPE
was performed using a C18 plus SepPak®. The productwas formulated
(8.5% EtOH), sterile ﬁltered and analyzed by analytical HPLC. The
retention times were 1.49 min (k’ = 0) for [18F]ﬂuoride, 3.03 min
(k’ = 0.66) for [18F]BFM, 3.62 min (k’ = 0.99) for Br2CD2, 4.03 min
(k’ = 1.21) for precursor NER and 5.42 min (k’ = 1.98) for product
[18F]FMeNER-D2, respectively. In Fig. 4, exemplary HPLC chromato-
grams (both preparative and analytical) are shown.4.3. Automation of synthesis
Full automation of [18F]FMeNER-D2 synthesis was achieved
successfully. [18F]Fluoride ﬁxation, azeotropic drying and reaction
with Br2CD2 were performed with high yields and purity. Automation
of distillation of [18F]BFM remained the crucial step within the
synthesis, where the major loss of activity occurred. About half of
the formed [18F]BFM was found to be retained on the Silica plus
cartridges when distilling with 40 mL/min He stream. However, the
amount of [18F]BFM trapped using 40 mL/min was sufﬁcient for the
following reaction and puriﬁcation. Increasing the ﬂow to 50 mL/min
and higher, did on the one hand result in higher activity trapped in the
second reactor, but separation from dibromomethane-d2 and ACN
could no longer be achieved quantitatively. Subsequently, almost
quantitative conversion of [18F]BFM to FMeNER-D2 was observed for
the automated large scale preparations.
So far, more than 25 fully automated radiosyntheses have been
performed, yielding 1.53 ± 0.6 GBq [18F]FMeNER-D2 (12.0% ± 5.2%,
not corrected for decay) within 100 min from the end of bombard-
ment (for details see Table 1). Speciﬁc radioactivities ranged from 430
to 1707 GBq/μmol. Radiochemical and chemical purity was al-
ways ≥ 98%, osmolality and pH were found to be in a physiological
range. GC analysis evinced ACN b10 ppm and methanol b20 ppm for
each batch. In TLC and analytical radio-HPLC presence of [18F]ﬂuoride
and [18F]BFE was quantiﬁed, and found to be b1%.
Fig. 4. Preparative and analytical HPLC chromatogram of [18F]FMeNER-D2.
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after release (4.7 MBq/kg body weight) to healthy volunteers and
ADHD patients. 120 min post injection, dynamic PET scans were
performed for 60 min. In Fig. 5, exemplary NET distribution maps
measured with PET and FMeNER-D2 in a health male subject are
shown (for details, see ﬁgure’s legend).
5. Discussion
Since so far only [18F]FMeNER-D2 is used as a feasible NET-PET
tracer in clinical trials, an automated radiosynthesis is of great beneﬁt
in terms of routine availability, reproducibility and radiation safety.
For evaluation of optimum parameters, small scale experiments
were performed. During the examinations, the puriﬁcation step of
[18F]BFM turned out to be the chokepoint of the synthesis. Within the
ﬁrst experiments, it rapidly turned out that distillation at 70 °C as
described by Schou et al. was not the method of choice. Thus, huge
amounts of ACN were found to be present in the DMF trap even when
very weak adjuvant gas ﬂow was applied and no matter which trap
was used (glass vial, Silca plus SepPak® and omniﬁt cartridges). The
presence of ACN, even in trace amounts, seems to impede the reaction
between NER and [18F]BFM, possibly due to the insolubility of NER in
ACN. Moreover, large quantities of Br2CD2 were found in the DMF trap
as well, leading to cold side product formation (BrMeNER) with
unknown, but expected high afﬁnity towards NET. Therefore, a milder
distillation procedure needed to be established, and was met when
applying 28 °C. This temperature seems to be high enough for the
highly volatile synthon [18F]BFM to be drawn by distillation, but low
enough to prevent evaporation of Br2CD2 and ACN. Thereby anTable 1
Fully automated preparation of [18F]FMeNER-D2: Yields, loss of radioactivity and
required time.
n ≥ 15 GBq % of initial activity
(corr. for decay)




activity in reactor 1








1.2 ± 0.3 7.7 ± 1.9 76 ± 1
[18F]FMeNER-D2
ﬁnal product yield




(range 432.7–1707.4)auxiliary gas stream of 40 mL/min was found to be optimal. Best
results were obtained when using 4 Silica plus SepPak® cartridges
linked in series.
Upon complete separation of ACN from the pure [18F]BFM solu-
tion, reaction with precursor NER yielded N95% radiochemical
incorporation of [18F]FMeNER-D2 in crude mixture. The puriﬁcation
of the product from [18F]BFM and NER was performed quantitatively
using the proposed preparative HPLC assaywith a retention time of 8–
9 min for [18F]FMeNER-D2. After SPE (using a C18 plus SepPak), pure
[18F]FMeNER-D2 was eluted almost quantitatively from the cartridge,
hence only 0.5%–2% of the pure product was bound irreversibly.
Satisfying amounts of product were achieved after formulation and
sterile ﬁltration. Strict radiopharmaceutical quality control was
passed for all synthesized batches allowing for preclinical testing
and in-vivo applications. Analytical HPLC evinced high speciﬁc acti-
vities (SA) for all lots of [18F]FMeNER-D2 produced. High variation
(430–1707 GBq/μmol) in SA was observed but can be explainedFig. 5. Parametric voxel-wise binding potential (BPND) maps of the norepinephrine
transporter superimposed on structural magnetic resonance images in a healthy
subject (male, age 21 years) using [18F]FMeNER-D2. The white cross in the triplanar
view indicates the thalamus (upper column) and the locus coeruleus (lower column),
the colour bar indicates the norepinephrine transporter binding potential. The BPND has
been calculated using a 2-tissue compartment model with the caudate as reference
region and the software PMOD 3.0. The injected dose was 416.6 MBq, the speciﬁc
activity was 520.6 GBq/μmol (corrected for application time). Note also the high uptake
in extracerebral areas.
1054 C. Rami-Mark et al. / Nuclear Medicine and Biology 40 (2013) 1049–1054likewise: The amount of non-radioactive FMeNER-D2 present in the
product was so small that it was below the limit of detection.
Therefore, the SAwas only dependent on the product yield. Hence, the
given values represented the lower limits in achieved SA, leading to
the observed variances.
Furthermore, we examined the inﬂuence of the quality of water
used for the ﬂuoride elution solution in preliminary tests. We
compared elution solution with ‘aqua ad injectabilia’, commonly
used for other tracer preparations, with the one made with ‘trace
select water’. Speciﬁc activity was found to be much lower (139.9 ±
69 GBq/μmol; range: 57.8–231 GBq/μmol, n ≥ 8) for ‘aqua ad inj.’ as
compared to the experiments with elution solutions containing ‘trace
select water’ (SA = 598.9 ± 352 GBq/μmol; range: 432.7–1707 GBq/
μmol n ≥ 15).
6. Conclusion
Automation of [18F]FMeNER-D2 synthesis was set-up successfully,
enabling a reliable and routine preparation of this NET-PET tracer
for clinical use. More than 25 fully automated syntheses were
performed yielding 1.53 ± 0.6 GBq [18F]FMeNER-D2 with high purity
and excellent speciﬁc radioactivities ready to use for animal or human
application. Enhancing the routine availability of [18F]FMeNER-D2
will lead to an increased interest in clinical trials regarding the
norepinephrine transporter using PET.
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